Moderna
MRNA · NASDAQ · Biotech · United States
$63.96
+15.5%
as of Jun 18, 2026, 8:00 PM
52-week range
$22.28 – $67.74
Revenue (FY2025)
$1.9B
Net margin
-145.2%
ROE
-32.6%
Volume
21,594,865
New to these? P/E, ROE, ROCE and more in Learn.
Ask MarketChacha about MRNA
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Financials
Revenue trend
Yearly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| FY2025 | $1.9B | $-2.8B | -7.26 | -145.2% | -32.6% |
| FY2024 | $3.2B | $-3.6B | -9.28 | -110.0% | -32.7% |
| FY2023 | $6.8B | $-4.7B | -12.33 | -68.8% | -34.0% |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| 2026Q1 | $389.0M | $-1.3B | -3.40 | -345.2% | — |
| 2025Q3 | $1.0B | $-200.0M | -0.51 | -19.7% | — |
| 2025Q2 | $142.0M | $-825.0M | -2.13 | -581.0% | — |
| 2025Q1 | $108.0M | $-971.0M | -2.52 | -899.1% | — |
| 2024Q3 | $1.9B | $13.0M | 0.03 | 0.7% | — |
| 2024Q2 | $241.0M | $-1.3B | -3.33 | -530.7% | — |
| 2024Q1 | $167.0M | $-1.2B | -3.07 | -703.6% | — |
| 2023Q3 | $1.8B | $-3.6B | -9.53 | -198.3% | — |
| 2023Q2 | $344.0M | $-1.4B | -3.62 | -401.2% | — |
| 2023Q1 | $1.9B | $79.0M | 0.19 | 4.2% | — |
Figures as reported, in reporting currency. Source: SEC XBRL.
Filings & announcements
2026
- SEC5/11/2026material
- SEC5/1/2026material
- SEC5/1/2026
- SEC3/5/2026material
- SEC2/20/2026
In the news
- Stock Market Today: Nasdaq, Russell 2000 Pace Rebound; SpaceX Slumps 24% Off Its Peak - Investor's Business Daily· Investor's Business Daily
- Moderna (NASDAQ:MRNA) Reaches New 1-Year High - Still a Buy? - MarketBeat· MarketBeat
- Moderna Stock Surges As Federal Health Regulators Clear Milestone Older Adult Flu Vaccine Data - TIKR.com· TIKR.com
- Why Is Moderna (MRNA) Stock Soaring Today - Yahoo Finance· Yahoo Finance
- The Surprising FDA View That Sent Moderna Stock Flying - Investor's Business Daily· Investor's Business Daily
- Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax? - 24/7 Wall St.· 24/7 Wall St.
- Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review - Stocktwits· Stocktwits
- Moderna (MRNA) Stock Valuation Check After Strong Year To Date Rebound - simplywall.st· simplywall.st
- Moderna (MRNA) Stock Looks Slightly Overvalued After Recent Rebound In Mixed Return Picture - Yahoo Finance· Yahoo Finance
- Moderna, Inc. $MRNA Shares Sold by Letko Brosseau & Associates Inc. - MarketBeat· MarketBeat
Education and discussion only — not investment advice. Data from official filings (SEC/BSE), Yahoo Finance, and Google News. Verify with the linked sources before acting.